Published in Virol J on September 07, 2005
Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology (2010) 2.83
Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells. J Virol (2009) 1.85
IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol (2010) 1.64
Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology (2011) 1.59
Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication. J Biol Chem (2008) 1.32
Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS One (2010) 1.26
Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users. J Viral Hepat (2010) 1.23
Viral induction of the zinc finger antiviral protein is IRF3-dependent but NF-kappaB-independent. J Biol Chem (2010) 1.13
Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent. Immunol Cell Biol (2012) 1.08
Innate immune responses in hepatitis C virus infection. Semin Immunopathol (2012) 1.06
Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B. Hepat Mon (2011) 1.06
IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection. Genes Immun (2011) 1.03
Genetic variation of the IL-28B promoter affecting gene expression. PLoS One (2011) 1.01
Interferon-λ in HCV Infection and Therapy. Viruses (2010) 0.98
Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cells. PLoS Pathog (2013) 0.97
Interferon-lambda in the immune response to hepatitis B virus and hepatitis C virus. J Interferon Cytokine Res (2010) 0.94
A new insight into hepatitis C vaccine development. J Biomed Biotechnol (2010) 0.94
Identification of the IFITM3 gene as an inhibitor of hepatitis C viral translation in a stable STAT1 cell line. J Viral Hepat (2011) 0.90
Transcriptional regulation of IFN-λ genes in hepatitis C virus-infected hepatocytes via IRF-3·IRF-7·NF-κB complex. J Biol Chem (2014) 0.88
IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult-to-treat hepatitis C virus infection. J Infect Dis (2011) 0.87
Characterization of HCV interactions with Toll-like receptors and RIG-I in liver cells. PLoS One (2011) 0.86
Retinoic acid inducible gene-I (RIG-I) signaling of hepatic stellate cells inhibits hepatitis C virus replication in hepatocytes. Innate Immun (2012) 0.84
Hepatitis C virus impairs TLR3 signaling and inhibits IFN-λ 1 expression in human hepatoma cell line. Innate Immun (2013) 0.84
Induction of interferon-λ contributes to Toll-like receptor-3-activated hepatic stellate cell-mediated hepatitis C virus inhibition in hepatocytes. J Viral Hepat (2013) 0.82
Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic. J Clin Transl Hepatol (2013) 0.79
The Correlation Between Interferon Lambda 3 Gene Polymorphisms and Susceptibility to Hepatitis B Virus Infection. Hepat Mon (2016) 0.79
Identification of pro-inflammatory cytokines associated with muscle invasive bladder cancer; the roles of IL-5, IL-20, and IL-28A. PLoS One (2012) 0.79
Hepatitis C virus and antiviral innate immunity: who wins at tug-of-war? World J Gastroenterol (2015) 0.78
Immune Cell Profiling of IFN-λ Response Shows pDCs Express Highest Level of IFN-λR1 and Are Directly Responsive via the JAK-STAT Pathway. J Interferon Cytokine Res (2016) 0.78
IFN-λ exerts opposing effects on T cell responses depending on the chronicity of the virus infection. J Immunol (2014) 0.77
New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents. Infect Drug Resist (2010) 0.75
EPSTI1 Is Involved in IL-28A-Mediated Inhibition of HCV Infection. Mediators Inflamm (2015) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (1994) 26.02
How cells respond to interferons. Annu Rev Biochem (1998) 24.27
Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A (1998) 13.39
Antiviral actions of interferons. Clin Microbiol Rev (2001) 13.06
IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol (2002) 11.87
IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol (2002) 11.22
Interferons and their actions. Annu Rev Biochem (1987) 8.36
Viruses and interferons. Annu Rev Microbiol (2001) 7.12
Effect of alpha interferon on the hepatitis C virus replicon. J Virol (2001) 6.18
Lambda interferon inhibits hepatitis B and C virus replication. J Virol (2005) 5.47
Interferons alpha and beta as immune regulators--a new look. Immunity (2001) 4.75
Structure of the human immune interferon gene. Nature (1982) 4.25
Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells. J Virol (2003) 4.06
Type I interferons keep activated T cells alive. J Exp Med (1999) 3.98
Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line. Hepatology (2003) 2.35
Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol (2002) 1.85
Interferon-induced human MxA GTPase blocks nuclear import of Thogoto virus nucleocapsids. Proc Natl Acad Sci U S A (1999) 1.78
Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology (2003) 1.76
Interferons: mechanisms of action and clinical applications. Curr Opin Oncol (2003) 1.56
Interferon type I gene expression in chronic hepatitis C. Lab Invest (2004) 1.55
The epidemiology of acute and chronic hepatitis C. Clin Liver Dis (1997) 1.36
JAK/STAT signaling by cytokine receptors. Curr Opin Immunol (1998) 1.36
Interleukin-1 inhibits hepatitis C virus subgenomic RNA replication by activation of extracellular regulated kinase pathway. J Virol (2003) 1.31
SOCS-1 inhibits expression of the antiviral proteins 2',5'-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29. Biochem Biophys Res Commun (2005) 1.29
PKR protection against intranasal vesicular stomatitis virus infection is mouse strain dependent. Viral Immunol (2002) 1.23
Are all type I human interferons equivalent? J Viral Hepat (1998) 1.12
Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma. Hepatology (1996) 1.07
Peginterferon alfa-2a: a review of approved and investigational uses. Clin Ther (2004) 1.05
Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action. J Interferon Cytokine Res (1999) 1.04
STAT3 induces anti-hepatitis C viral activity in liver cells. Biochem Biophys Res Commun (2004) 1.04
Hepatitis C virus core protein induces apoptosis and impairs cell-cycle regulation in stably transformed Chinese hamster ovary cells. Hepatology (2000) 1.04
The nature of interferon-alpha resistance in hepatitis C virus infection. Curr Opin Infect Dis (2003) 1.04
Diversity and relatedness among the type I interferons. J Interferon Cytokine Res (2004) 1.01
Interleukin-3 and interferon beta cooperate to induce differentiation of monocytes into dendritic cells with potent helper T-cell stimulatory properties. Blood (2002) 0.97
Vaccine development for hepatitis C. Semin Liver Dis (2000) 0.94
Stabilized beta-catenin promotes hepatocyte proliferation and inhibits TNFalpha-induced apoptosis. Lab Invest (2004) 0.94
Interferon signal transduction. Biotherapy (1996) 0.85
Regulation of HLA class I loci by interferons. Immunobiology (1995) 0.83
Interacting pathways of interferon signaling. Semin Oncol (1997) 0.83
The Chlamydomonas genome reveals the evolution of key animal and plant functions. Science (2007) 11.15
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
The Physcomitrella genome reveals evolutionary insights into the conquest of land by plants. Science (2007) 8.12
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31
Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res (2011) 5.97
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 5.29
Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med (2002) 3.94
Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation (2011) 3.81
The Ectocarpus genome and the independent evolution of multicellularity in brown algae. Nature (2010) 3.60
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology (2004) 3.18
Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med (2012) 3.17
Genetic drift at expanding frontiers promotes gene segregation. Proc Natl Acad Sci U S A (2007) 3.14
The Selaginella genome identifies genetic changes associated with the evolution of vascular plants. Science (2011) 3.10
Orientation discrimination of single-stranded DNA inside the alpha-hemolysin membrane channel. Proc Natl Acad Sci U S A (2005) 3.06
Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity (2012) 2.99
The African coelacanth genome provides insights into tetrapod evolution. Nature (2013) 2.78
Virus shapes and buckling transitions in spherical shells. Phys Rev E Stat Nonlin Soft Matter Phys (2003) 2.74
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med (2014) 2.54
Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis. Crit Care Med (2004) 2.48
Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A (2004) 2.41
Genomic analysis of detoxification genes in the mosquito Aedes aegypti. Insect Biochem Mol Biol (2007) 2.38
Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line. Hepatology (2003) 2.35
The genome of Nectria haematococca: contribution of supernumerary chromosomes to gene expansion. PLoS Genet (2009) 2.29
An integrated clinico-metabolomic model improves prediction of death in sepsis. Sci Transl Med (2013) 2.23
Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest (2008) 2.23
Direct visualization of dislocation dynamics in grain-boundary scars. Nat Mater (2005) 2.22
Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood (2008) 2.21
Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology (2010) 2.20
Gene surfing in expanding populations. Theor Popul Biol (2007) 2.19
Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med (2005) 2.12
IL-17 contributes to CD4-mediated graft-versus-host disease. Blood (2008) 2.07
DNA unzipped under a constant force exhibits multiple metastable intermediates. Proc Natl Acad Sci U S A (2003) 2.06
Is worsening multiple organ failure the cause of death in patients with severe sepsis? Crit Care Med (2011) 2.04
Effect of cigarette smoking on levels of seminal oxidative stress in infertile men: a prospective study. Fertil Steril (2002) 1.97
Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice. Blood (2011) 1.97
Foldable structures and the natural design of pollen grains. Proc Natl Acad Sci U S A (2010) 1.97
Single molecule statistics and the polynucleotide unzipping transition. Phys Rev E Stat Nonlin Soft Matter Phys (2002) 1.94
Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol (2004) 1.91
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology (2009) 1.90
Identification of liver cancer-specific aptamers using whole live cells. Anal Chem (2008) 1.90
A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med (2005) 1.88
Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl (2006) 1.86
PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl (2011) 1.85
Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res (2010) 1.84
C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study. Lancet (2002) 1.80
Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. J Exp Med (2011) 1.78
Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology (2003) 1.76
Sexual dysfunction in men undergoing infertility evaluation: a cohort observational study. Fertil Steril (2003) 1.76
Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology (2007) 1.75
Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial. Crit Care Med (2004) 1.73
Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells. Blood (2011) 1.72
Cyclooxygenase-2 and Akt mediate multiple growth-factor-induced epithelial-mesenchymal transition in human hepatocellular carcinoma. J Gastroenterol Hepatol (2012) 1.70
LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease. Blood (2003) 1.67
Cytolytic T cells induce ceramide-rich platforms in target cell membranes to initiate graft-versus-host disease. Blood (2009) 1.67
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology (2008) 1.66
Negative effects of increased sperm DNA damage in relation to seminal oxidative stress in men with idiopathic and male factor infertility. Fertil Steril (2003) 1.66
Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland. Mod Pathol (2009) 1.65
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
Manipulating the bioenergetics of alloreactive T cells causes their selective apoptosis and arrests graft-versus-host disease. Sci Transl Med (2011) 1.61
Genome of the long-living sacred lotus (Nelumbo nucifera Gaertn.). Genome Biol (2013) 1.59
Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis. Clin J Am Soc Nephrol (2006) 1.59
Critical role of host gammadelta T cells in experimental acute graft-versus-host disease. Blood (2005) 1.58
Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med (2004) 1.58
Cellular FLICE-inhibitory protein protects against cardiac remodeling induced by angiotensin II in mice. Hypertension (2010) 1.57
Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C Semin Med Genet (2014) 1.57
The 2008 update of the Aspergillus nidulans genome annotation: a community effort. Fungal Genet Biol (2008) 1.56
Life at the front of an expanding population. Evolution (2009) 1.56
Pyrosequencing the transcriptome of the greenhouse whitefly, Trialeurodes vaporariorum reveals multiple transcripts encoding insecticide targets and detoxifying enzymes. BMC Genomics (2011) 1.53
Cytochrome p450 complement (CYPome) of the avermectin-producer Streptomyces avermitilis and comparison to that of Streptomyces coelicolor A3(2). Biochem Biophys Res Commun (2003) 1.52
Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. Blood (2005) 1.51
Impact of implementation of the MELD scoring system on the prevalence and incidence of chronic renal disease following liver transplantation. Liver Transpl (2006) 1.49
Disruption of mindin exacerbates cardiac hypertrophy and fibrosis. J Mol Med (Berl) (2012) 1.48
Development of an inexpensive artificial vagina for semen collection from rabbits. J Androl (2003) 1.47
Genetic demixing and evolution in linear stepping stone models. Rev Mod Phys (2010) 1.46
CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant. Liver Int (2012) 1.46
Role of CXCR3-induced donor T-cell migration in acute GVHD. Exp Hematol (2003) 1.46
Nanoparticle-based artificial RNA silencing machinery for antiviral therapy. Proc Natl Acad Sci U S A (2012) 1.45
CCR2 is required for CD8-induced graft-versus-host disease. Blood (2005) 1.43
Helicobacter pylori detection by polymerase chain reaction in pediatric gastritis. J Pediatr Gastroenterol Nutr (2012) 1.43
Presentation and management of gastrointestinal stromal tumors of the duodenum. Am Surg (2006) 1.42
Non-immunologic vascular failure of the transplanted heart. J Heart Lung Transplant (2003) 1.40
Duplicate gallbladder arising from the left hepatic duct: report of a case. Surg Today (2009) 1.39
Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. Clin Exp Metastasis (2011) 1.37
Identification and developmental expression of the full complement of Cytochrome P450 genes in Zebrafish. BMC Genomics (2010) 1.37
T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease. Biol Blood Marrow Transplant (2009) 1.37
DNA aptamers as molecular probes for colorectal cancer study. PLoS One (2010) 1.36
Magnetic resonance imaging-based cartilage loss in painful contralateral knees with and without radiographic joint space narrowing: Data from the Osteoarthritis Initiative. Arthritis Rheum (2009) 1.34
Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin Infect Dis (2003) 1.33
Focal distribution of hepatitis C virus RNA in infected livers. PLoS One (2009) 1.32